Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross TN Zusduri Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - TennesseePolicy ID_CHS_70372026_1126

    Mitomycin (Zusduri)

    Customize your policy alerts

    Sign up for blue cross blue shield - tennessee Policy ID_CHS_70372026_1126 alerts

    Get alerted when Policy ID_CHS_70372026_1126 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage of intravesical Zusduri (mitomycin) for adult members with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and compendial non-muscle invasive bladder cancer use. Coverage requires satisfaction of the stated treatment criteria and absence of exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyMitomycin (Zusduri)
    Policy CodePolicy ID_CHS_70372026_1126
    Change TypeNo material clinical or coverage changes
    Effective DateJan 30, 2027
    Next Review DateN/A
    Key ActionObtain prior authorization; approval may be granted for 3 months and 6 doses when all coverage criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3 monthsMaximum authorization duration
    6 dosesDoses authorized per course
    Once weekly x6Required administration schedule
    Adult recurrent LG-IR-NMIBCFDA-approved covered indication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Not medically necessary
    Other indications

    Coverage Criteria

    Initial bladder cancer treatment

    Covered when all of the following are met:

    Bladder cancer treatment criteria

    • Disease indication: The member has recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

      Intermediate-risk features may include multiple tumors, a solitary tumor greater than 3 cm, and/or early or frequent recurrence.

    • Administration route: The requested drug will be given via intravesical instillation.
    • Administration schedule: The requested drug will be administered once weekly for six weeks.Once weekly for 6 weeks
    • Surgery restriction: The member will not receive surgery as part of the current course of treatment.

    Continuation therapy

    Continuation therapy is covered only when all requirements in the coverage criteria section continue to be met:

    • Coverage criteria: All requirements in the coverage criteria section must be met for continuation authorization.

    Coverage is available only when all approval criteria are met and the member has no exclusion to the prescribed therapy. If an exclusion applies, coverage is not available.

    Indications outside the FDA-approved indication and the listed compendial use of non-muscle invasive bladder cancer are considered experimental/investigational and not medically necessary.

    Initial Zusduri Therapy

    Initial Zusduri therapy

    Authorization of 3 months and 6 doses may be granted when all of the following criteria are met:

    • Disease indication: The member has recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

      Intermediate-risk features may include multiple tumors, a solitary tumor greater than 3 cm, and/or early or frequent recurrence.

    • Administration route: The requested drug will be given via intravesical instillation.
    • Administration schedule: The requested drug will be administered once weekly for six weeks.Once weekly for 6 weeks

    Continuation of Therapy

    Continuation of therapy

    All members, including new members, requesting continuation of therapy must meet all requirements in the coverage criteria section.

    • Coverage criteria: All requirements in the coverage criteria section must be met for continuation authorization.

    Provider Actions and Coverage Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. When criteria are met, authorization may be granted for 3 months and a maximum of 6 doses for treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

    • Authorization period: 3 months.
    • Quantity limit: 6 doses.
    Denial Risk

    Unapproved or Unsupported Indication

    Uses other than the covered FDA-approved indications or compendial use of non-muscle invasive bladder cancer (NMIBC) are considered experimental/investigational and not medically necessary.

    • Covered compendial use: non-muscle invasive bladder cancer (NMIBC).

    Clinical Background

    Zusduri (mitomycin) is covered for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Intermediate-risk features may include multiple tumors, a solitary tumor greater than 3 cm, and/or early or frequent recurrence. Non-muscle invasive bladder cancer is also identified as a compendial use under this policy.

    Key Definitions

    LG-IR-NMIBC
    TermLG-IR-NMIBC
    DefinitionRecurrent low-grade intermediate-risk non-muscle invasive bladder cancer in adult patients
    Intermediate-risk examplePresence of multiple tumors
    Intermediate-risk exampleA solitary tumor greater than 3 cm
    Intermediate-risk exampleEarly or frequent recurrence
    NMIBC
    TermNMIBC

    Quantity and Authorization Limits

    Quantity Limits
    DrugZusduri (mitomycin)
    Quantity limit6 doses per course
    Authorization period3 months

    Administration Site and Route

    Billing Rule

    Administer the drug intravesically

    The requested drug must be administered via intravesical instillation.

    Policy Summary
    PayerBlue Cross Blue Shield - Tennessee
    PolicyMitomycin (Zusduri)
    Policy CodePolicy ID_CHS_70372026_1126
    Change TypeNo material clinical or coverage changes
    Effective DateJan 30, 2027
    Next Review DateN/A
    Key ActionObtain prior authorization; approval may be granted for 3 months and 6 doses when all coverage criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaInitial Zusduri TherapyContinuation of TherapyProvider Actions and Coverage RisksClinical BackgroundKey DefinitionsQuantity and Authorization LimitsAdministration Site and Route
    Surgery restriction: The member will not receive surgery as part of the current course of treatment.
  1. All other indications are unapproved or unsupported and are not medically necessary.
  2. Unsupported block type: denial_riskある?

    Denial Risk

    Approval Criteria and Exclusions

    The indication is covered only when all approval criteria are met and the member has no exclusions to the prescribed therapy.

    • Confirm the member has recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, such as multiple tumors, a solitary tumor greater than 3 cm, and/or early or frequent recurrence.
    • Verify that every applicable approval criterion is satisfied.
    • Confirm that no exclusion applies to the prescribed therapy.
    Definition
    Non-muscle invasive bladder cancer
    Policy useListed as a compendial use for Zusduri (mitomycin)